Document:

Exhibit 10.4

 

This Agreement
(the “Agreement”), dated as of March 13, 2015 (the “Effective Date”), by and among Oculus
Innovative Sciences, Inc., a Delaware corporation, with its principal place of business at 1129 N. McDowell Blvd., Petaluma, CA
94954 (“Oculus”), Ruthigen, Inc., a Delaware corporation, with its principal place of business at 2455 Bennett
Valley Road, Suite C116, Santa Rosa, CA 95404 (“Ruthigen”) and Hoji Alimi.

 

Reference is made to (i) that certain License
and Supply Agreement, dated May 23, 2013, as amended on October 9, 2013, November 6, 2013 and January 31, 2014, by and among Ruthigen
and Oculus (the “License and Supply Agreement”), (ii) that certain Separation Agreement, dated August 2, 2013,
as amended on January 31, 2014, by and between Ruthigen and Oculus (the “Separation Agreement”), and (iii) that
certain Shared Services Agreement, dated May 23, 2013, as amended on January 31, 2014, by and between Ruthigen and Oculus (the
“SSA” and collectively with the License and Supply Agreement, the Separation Agreement and any other agreements
or understandings (whether written or oral) between Ruthigen and Oculus, the “Oculus Agreements”).

 

NOW, THEREFORE, for and in consideration
of the premises, the mutual agreements and covenants herein contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

	1.	Termination of Shared Services Agreement.
	 	 
	 	As of the Effective Date, the
SSA shall be mutually terminated, if not previously terminated, and be of no further force and effect.

  

	2.	Amendment of the License and Supply Agreement.
	 	 
	 	As of the Effective Date, the
License and Supply Agreement is hereby amended as follows:

(i) The definition of “Field”
is deleted in its entirety and the following definition is inserted in lieu thereof: “Field” means the surgical irrigation
drug product indications(s) set forth in the Development and Commercialization Plan attached as Schedule 3 to the License and Supply
Agreement;

(ii) The definition of “Invasive”
is deleted in its entirety;

(iii) The definition of “Product”
is deleted in its entirety and the following definition is inserted in lieu thereof: “Product” means any sterile prescription
drug product for use in the Field in the Territory;

(iv) Section 2.1(b) is deleted
in its entirety;

(v) Section 6.13 is deleted
in its entirety and the words “Intentionally Omitted” are inserted in lieu thereof.

 

	3.	NON-COMPETE. Hoji Alimi acknowledges and recognizes the highly competitive nature of the
business of Oculus, the amount of sensitive and confidential information involved in the discharge of Hoji Alimi’s former
position with Oculus, and the harm to Oculus that would result if such knowledge or expertise was disclosed or made available to
a competitor. Based on that understanding, Hoji Alimi hereby expressly agrees as follows:
	 	 
	 	

As a result of the particular
nature of Hoji Alimi’s past and present relationship with Oculus for the period of one year from the Effective Date hereby
agrees that he will not, directly or indirectly, (i) engage in any business for his own account or otherwise derive any personal
benefit from any business that competes with the business of Oculus or any of its affiliates (Oculus and its affiliates are referred
to, collectively, as the “Company Group”), (ii) enter the employ of, or render any services to, any person engaged
in any business that competes with the business of any entity within the Company Group, (iii) acquire a financial interest in any
person engaged in any business that competes with the business of any entity within the Company Group, directly or indirectly,
as an individual, partner, member, shareholder, officer, director, principal, agent, trustee, or consultant, or (iv) interfere
with business relationships (whether formed before or after the Effective Date) between Oculus, any of its respective affiliates
or subsidiaries, and any customers, suppliers, officers, employees, partners, members or investors of any entity within the Company
Group. For purposes of this Agreement, businesses in competition with the Company Group shall include, without limitation, businesses
which any entity within the Company Group may conduct operations, and any business which any entity within the Company Group has
specific plans to conduct operations in the future and as to which Hoji Alimi is aware of such planning, whether or not such businesses
have or have not as of that date commenced operations.

 

    	1

    	 

    

 

	4.	EFFECT OF THIS AGREEMENT. Except as specifically amended as set forth herein, each term
and condition of the License and Supply Agreement shall continue in full force and effect.

 

	5.	GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the
laws in force in the State of California, without giving effect to the choice of laws provisions thereof.

 

	6.	COUNTERPARTS; FACSIMILE SIGNATURES. This Agreement may be executed or consented to in counterparts,
each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument. This Agreement
may be executed and delivered by facsimile or electronically and, upon such delivery, the facsimile or electronically transmitted
signature will be deemed to have the same effect as if the original signature had been delivered to the other party.

 

 

	 	Oculus Innovative Sciences, Inc.
	 	 	 
	 	 	 
	 	By: 	/s/ Jim Schutz
	 	Name: 	Jim Schutz
	 	Title:	Chief Executive Officer
	 	 	 
	 	 	 
	 	Ruthigen, Inc.
	 	 	 
	 	 	 
	 	By:	/s/ Hoji Alimi
	 	Name:	Hoji Alimi
	 	Title:	Chief Executive Officer
	 	 	 
	 	 	 
	 	Hoji Alimi
	 	 
	 	/s/ Hoji Alimi
	 	 	 

 

    	2Exhibit 4.9

 

EXHIBIT B

 

FORM OF WARRANT

 

NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS WARRANT IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN A SECURITIES PURCHASE AGREEMENT, DATED AS OF NOVEMBER 9, 2014, AND AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY.

 

GTX, INC.

 

COMMON STOCK WARRANT

 

	
Warrant   No. CSW2014-[·]
    	
Date of Original Issuance:  November [·], 2014
    

 

GTx, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, [·], or its registered assign (the “Holder”), is entitled, subject to Section 6(c) hereof, to purchase from the Company [·] shares (as adjusted from time to time as provided in Section 11) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”), at the Exercise Price determined pursuant to Section 3 hereof, at any time and from time to time from and after the earlier of (i) the date that Stockholder Approval is first obtained or (ii) the Trading Day immediately prior to the occurrence of a Fundamental Transaction but in no event later than June 1, 2015 (the “Initial Exercisability Date”) through and including the fourth anniversary of the Initial Exercisability Date (the “Expiration Date”), and subject to the following terms and conditions:

 

1.                                      Purchase Agreement.  This Common Stock Warrant (this “Warrant”) is one of the Warrants issued by the Company in connection with that certain Securities Purchase Agreement, entered into on November 9, 2014 (as amended from time to time, the “Purchase Agreement”), by and among the Company and Holder and certain other Purchasers, and is subject to, and the Company and the Holder shall be bound by, all the applicable terms, conditions and provisions of the Purchase Agreement.

 

2.                                      Definitions.  In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement.  As used herein, the following terms shall have the following respective meanings:

 

(a)                                 “Bloomberg” means Bloomberg, L.P.

 

(b)                                 “Closing Sale Price” means, for the Common Stock the last closing trade price for such security on the Principal Trading Market, as reported by Bloomberg, or, if the Principal Trading Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg.

 

(c)                                  “Daily Trading Volume” means, for any Trading Day, the daily trading volume for the Common Stock, as reported by Bloomberg, on such Trading Day.

 

1

 

(d)                                 “Eligible Market” means any of the NYSE MKT, The NASDAQ Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).

 

(e)                                  “Fair Market Value” of one share of Common Stock on the Date of Exercise (as hereinafter defined) means (i) the VWAP for the Trading Day immediately prior to the Date of Exercise, or (ii) if an Eligible Market is not then the Principal Trading Market, the average of the reported sales prices reported by Bloomberg on the Trading Market for the Common Stock on the Trading Day immediately prior to the Date of Exercise, or, if there is no sales price on such Trading Day, the last sales price reported by Bloomberg for such Trading Day, or (iii) if neither of the foregoing applies, the last sales price of the Common Stock in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC) (or any similar organization or agency succeeding to its functions of reporting prices) for the Common Stock as reported by Bloomberg, or if no sales price is so reported for the Common Stock, the last bid price of such Common Stock as reported by Bloomberg or (iv) if fair market value cannot be calculated as of such date on any of the foregoing bases, the fair market value shall be as determined by the Board of Directors in the exercise of its good faith judgment.

 

(f)                                   “Issuance Date” means November [·], 2014, the date this Warrant was originally issued.

 

(g)                                  “Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading.

 

(h)                                 “Shares” means the Company’s currently authorized common stock, $0.001 par value, and stock of any other class or other consideration into which such currently authorized capital stock may hereafter have been changed.

 

(i)                                     “Trading Day” means (a) a day on which the Common Stock is listed or quoted and traded on the Principal Trading Market (other than the OTC Bulletin Board), or (b) if the Common Stock is not then listed or quoted and traded on any Eligible Market, then a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (c) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC) (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (a), (b) and (c) hereof, then Trading Day shall mean a Business Day.

 

(j)                                    “Trading Market” means the OTC Bulletin Board or any Eligible Market, or any national securities exchange, market or trading or quotation facility on which the Common Stock is then listed or quoted.

 

(k)                                 “Trigger Period”  means any thirty (30) consecutive Trading Day period during which (i) the VWAP has been at least $2.00 (as adjusted for any stock splits, stock dividends, recapitalizations or the like after the Issuance Date) for at least fifteen (15) of the Trading Days (whether or not consecutive) of such period, (ii) the average of the Daily Trading Volume, as measured over the same fifteen (15) Trading Days (whether or not consecutive) of such period, was at least 300,000 shares (as adjusted for any stock splits, stock dividends, recapitalizations or the like after the Issuance Date), and (iii) Stockholder Approval of the Increased Shares Amendment shall have been obtained prior to the start of such thirty (30) Trading Day measurement period.

 

(l)                                     “VWAP” shall mean the daily volume weighted average price (based on a Trading Day from 9:30 a.m. to 4:00 p.m. (New York time)) of the Common Stock on the Principal Trading Market as reported by Bloomberg Financial L.P. using the AQR function.

 

3.                                      Exercise Price. This Warrant may be exercised for a price per Warrant Share equal to $0.85, subject to adjustment from time to time pursuant to Section 11 (the “Exercise Price”).

 

4.                                      Registration of Warrant. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to

 

2

 

time. The Company may deem and treat the Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

5.                                      Transfer of Warrant.

 

(a)                                 No Holder may, directly or indirectly, sell, exchange, assign or otherwise transfer all or any portion of this Warrant without the prior written consent of the Company; provided that, subject in each case to Section 5(b) hereof, (i) a Holder that is a natural person may transfer all or a portion of this Warrant to one or more trusts for the benefit of such Holder, such Holder’s spouse, a lineal descendant of such Holder or such Holder’s parents, the spouse of any such descendant or a lineal descendant of any such spouse and (ii) a Holder that is a Person other than a natural person may transfer all or a portion of the Warrant to an Affiliate of such Holder.

 

(b)                                 Subject to the Holder’s appropriate compliance with the restrictive legend on this Warrant and the transfer restrictions set forth herein and in the Purchase Agreement, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon (i) surrender of this Warrant, with the Form of Assignment substantially in the form attached hereto as Attachment B duly completed and signed, to the Company at its address specified herein and (ii) delivery to the Company at its address specified herein an investment letter, in form and substance reasonably satisfactory to the Company, signed by the transferee. Upon any such registration or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

6.                                      Duration and Exercise of Warrants; Mandatory Exercise; Mandatory Cash Settlement.

 

(a)                                 Duration. This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the Initial Exercisability Date and through and including the Expiration Date (the “Exercise Period”). At 6:30 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value.

 

(b)                                 Mandatory Exercise.

 

(i)                                     Notwithstanding anything in this Warrant or in the Purchase Agreement to the contrary, if at any time after May [·], 2016(1) a Trigger Period shall occur, then (provided that as of Mandatory Exercise Notice Date (as defined below) the Principal Trading Market is an Eligible Market), the Company shall have the right to require the Holder to exercise this Warrant for all of the then-remaining Warrant Shares or any portion thereof, as further set forth below (the “Mandatory Exercise Right”).

 

(ii)                                  The Company may exercise the Mandatory Exercise Right (to the extent permitted hereby) by delivering, within ten (10) Trading Days following the end of any Trigger Period, written notice thereof to the Holder (the “Mandatory Exercise Notice” and the date such notice is deemed given and effective pursuant to Section 18(a) hereof is referred to as the “Mandatory Exercise Notice Date”), which such Mandatory Exercise Notice shall state (x) that the Company is electing the Mandatory Exercise Right and (y) the portion (if less than all) of this Warrant for which the Company is electing the Mandatory Exercise Right, and the Holder shall thereafter effect the exercise of this Warrant (or, at a minimum, the portion thereof indicated in the Mandatory Exercise Notice) within ten (10) Trading Days following the Mandatory Exercise Notice Date (the “Mandatory Exercise Date Deadline”). If the Company has exercised its Mandatory Exercise Right pursuant to this Section 6(b) and the Holder has not effected the exercise of this Warrant by the Mandatory Exercise Date Deadline as required by this Section 6(b), then this Warrant shall be deemed automatically exercised as if the Company had received from the Holder on the Mandatory Exercise Date Deadline an Exercise Notice with respect to the exercise of this Warrant for the number of Warrant Shares so indicated in the Mandatory Exercise Notice, in which case, (x)

 

(1)  This date shall be the date 18 months following the Closing.

 

3

 

the Mandatory Exercise Date Deadline shall be deemed the Date of Exercise and (y) this Warrant (or the portion thereof indicated in the Mandatory Exercise Notice) shall be automatically exercised pursuant to the “net exercise” provisions of Section 7(b) hereof (unless Mandatory Cash Settlement is then required pursuant to Section 6(c), in which case, such automatic exercise shall be settled in the manner provided under Section 6(c)). To the extent this Warrant is deemed to be automatically exercised pursuant to this Section 6(b) in full, the Company will not be required to settle such exercise unless and until the Holder physically surrenders this Warrant to the Company.

 

(iii)                               If the Company elects a Mandatory Exercise Right pursuant to this Section 6(b), then the Company must take the same action with respect to all of the other Warrants then outstanding.  For purposes of this Section 6(b)(iii), in the event the Company elects a Mandatory Exercise Right for only a portion of this Warrant, then the requirement in the foregoing sentence shall be applied on a pro rata basis based on the total number of then-remaining shares of Common Stock subject to this Warrant and each of the other Warrants then outstanding.

 

(iv)                              Subject to the other provisions of this Section 6(b), the Company may elect a Mandatory Exercise Right on more than one occasion.

 

(c)                                  Mandatory Cash Settlement.

 

(i)                                     Notwithstanding anything in this Warrant or in the Purchase Agreement to the contrary, if at any time during the Exercise Period, (i) Stockholder Approval of the Increased Shares Amendment has not been obtained and/or (ii) there are then an insufficient number of authorized and reserved shares of Common Stock to provide for the exercise of the rights represented by this Warrant, then this Warrant may not be exercised for Warrant Shares and the Company shall instead settle any exercises of this Warrant by making a cash payment to the Holder, in the amount as determined below (and in lieu of delivery of the number of Warrant Shares so indicated by the Holder to be purchased upon any such exercise) (such cash settlement, a “Mandatory Cash Settlement”). In the event of a Mandatory Cash Settlement pursuant to this Section 6(c), in lieu of delivery of any Warrant Shares upon such exercise, the Company shall pay to the Holder an amount in cash equal to the result obtained by multiplying (a) the number of Warrant Shares so indicated by the Holder to be purchased upon such exercise as set forth in the Holder’s Exercise Notice (as defined below) by (b) the excess of (i) the Fair Market Value of one share Common Stock on the Date of Exercise, over (ii) the Exercise Price (such amount, the “Cash Settlement Payment”). In the event of a Mandatory Cash Settlement pursuant to this Section 6(c), the Company shall pay the Holder the Cash Settlement Payment as soon as reasonably practical after the Date of Exercise, and in any event within three (3) Trading Days thereafter. For the avoidance of doubt, if the Fair Market Value of one share Common Stock on the Date of Exercise is less than the Exercise Price, then no Cash Settlement Payment shall be payable to the Holder.

 

(ii)                                  On or prior to the Initial Exercisability Date, the Company shall deliver a written notice to the Holder indicating whether Mandatory Cash Settlement is required under this Section 6(c) as of the Initial Exercisability Date. In the event that Mandatory Cash Settlement is required under this Section 6(c) as of the Initial Exercisability Date, then as soon as reasonably practicable following the date on which Mandatory Cash Settlement is no longer required under this Section 6(c), the Company shall deliver a written notice to the Holder indicating that Mandatory Cash Settlement is no longer required under this Section 6(c) (the “Revocation Notice”). From and after the earlier of (x) the Authorized Shares Increase Date or (y) the date of the Revocation Notice, the provisions of this Section 6(c) shall automatically become inoperative and shall have no further force or effect, and thereafter, this Warrant shall be exercisable only for Warrant Shares.

 

(d)                                 Subject in all cases to the provisions of Section 6(c) hereof, not later than three (3) Trading Days after each Date of Exercise (the “Share Delivery Date”), the Company shall deliver, or cause to be delivered, to the Holder a certificate representing the Warrant Shares which, to the extent provided in the Purchase Agreement, shall be free of restrictive legends and trading restrictions representing the number of Warrant Shares being acquired upon the exercise of the Warrant.  If, on any applicable Share Delivery Date, such certificate(s) (or the Cash Settlement Payment in lieu thereof in the event Mandatory Cash Settlement is then required pursuant to Section 6(c)) are not timely delivered to or as directed by the Holder, then the Holder shall be entitled to elect by written notice to the Company at any time on or before its receipt of such certificate(s), to rescind such exercise, in which event the Company shall promptly return to the Holder the original Warrants (if any) delivered to the

 

4

 

Company and if applicable, the Holder shall promptly return to the Company the Common Stock book-entry statements issued to such Holder pursuant to the rescinded Exercise Notice.

 

(e)                                   In connection with any exercise of this Warrant (other than any exercise that is subject to Mandatory Cash Settlement as provided in Section 6(c)), if the Company shall fail for any reason to deliver the Warrant Shares by the Share Delivery Date, and if on or after the Share Delivery Date the Holder purchases (in an open market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by the Holder of any portion of such Warrant Shares that the Holder anticipated receiving by the Share Delivery Date (a “Buy-In”), then the Company shall, within three (3) Trading Days after the Holder’s request and in the Holder’s discretion, either: (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the number of Warrant Shares so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such Warrant Shares shall terminate, or (ii) promptly honor its obligation to deliver to the Holder such Warrant Shares as provided above and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of Common Shares, times (B) the Exercise Price.

 

7.                                      Delivery of Warrant Shares or Cash Settlement Payment on Exercise; Net Exercise.

 

(a)                                 To effect exercises hereunder, the Holder shall not be required to physically surrender this Warrant, and unless this Warrant is surrendered upon such exercise, the execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares (if any). Upon delivery of an Exercise Notice substantially in the form attached hereto as Attachment A (an “Exercise Notice”) to the Company at its address for notice determined as set forth herein, and, unless Mandatory Cash Settlement is then required pursuant to Section 6(c), upon payment of the Exercise Price for the number of Warrant Shares so indicated by the Holder to be purchased (which may take the form a “net exercise” as permitted pursuant to Section 7(b) and so indicated in the Exercise Notice), the Company shall promptly (but in no event later than three (3) Trading Days after the Date of Exercise) either (x) pay the Holder the Cash Settlement Payment in the event Mandatory Cash Settlement is then required pursuant to Section 6(c) or (y) in the event Mandatory Cash Settlement is not then required pursuant to Section 6(c), issue and deliver, or cause its transfer agent to issue and deliver, to the Holder a certificate for the Warrant Shares issuable upon such exercise registered in the name of the Holder or its designee. A “Date of Exercise” means the date on which the Holder shall have delivered to the Company: (i) an Exercise Notice, appropriately completed and duly signed, and (ii) unless either (x) Mandatory Cash Settlement is then required pursuant to Section 6(c) or (y) the exercise of this Warrant is being effected as a “net exercise” pursuant to Section 7(b), as applicable, payment of the Exercise Price (by certified or official bank check, intra-bank account transfer or wire transfer) for the number of Warrant Shares so indicated by the Holder to be purchased.

 

(b)                                 Subject in all cases to the provisions of Section 6(c) hereof, in lieu of exercising this Warrant by payment of cash, the Holder may, at its election, effect a “net exercise” of this Warrant as indicated in the Holder’s Exercise Notice, in which event, if so effected, the Holder shall be entitled to receive Warrant Shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company, if applicable, together with the appropriately completed and duly signed Exercise Notice, in which event the Company shall issue to the Holder a number of Warrant Shares computed using the following formula:

 

	
 
    	
X  =
    	
Y*(A-B)
    	
 
    
	
 
    	
 
    	
A
    	
 
    

 

Where:

 

X =                             the number of Warrant Shares to be issued to the Holder

 

Y =                             the number of Warrant Shares with respect to which this Warrant is being exercised

 

A =                             the Fair Market Value of one share of Common Stock (as of the Date of Exercise)

 

5

 

B =                             Exercise Price (as of the Date of Exercise)

 

For the avoidance of doubt, if the foregoing calculation results in zero or a negative number, then no Warrant Shares shall be issued upon exercise pursuant to this Section 7(b).

 

(c)                                  Subject in all cases to the provisions of Section 6(c) hereof, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity, including a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Cash Settlement Payment or certificates representing shares of Common Stock upon exercise of the Warrant, as applicable, in each case as required pursuant to the terms hereof; provided, however, that, unless Mandatory Cash Settlement is then strictly required pursuant to Section 6(c) or Section 11(b), under no circumstances shall the Company be required to settle any exercises of this Warrant by cash payment or to otherwise “net cash settle” this Warrant.

 

8.                                      Charges, Taxes and Expenses. Issuance and delivery of certificated or uncertificated shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee, or other incidental tax or expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares or a Cash Settlement Payment, as applicable, upon exercise hereof.

 

9.                                      Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a new warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a new warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver this mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the new warrant.

 

10.                               Reservation of Warrant Shares. The Company covenants that, from and after the Authorized Shares Increase Date, the Company will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from liens, encumbrances or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 11). The Company covenants and warrants that, from and after the Authorized Shares Increase Date, all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable.

 

11.                               Certain Adjustments. The Exercise Price and the number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this Section 11.

 

(a)                                 Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into

 

6

 

a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company; then in each such case (A) the Exercise Price will be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which equals the number of shares of Common Stock outstanding immediately prior to such event (excluding treasury shares, if any), and the denominator of which equals the number of shares of Common Stock outstanding immediately after such event (excluding treasury shares, if any), and (B) the number of Warrant Shares issuable hereunder shall be concurrently adjusted by multiplying such number by the reciprocal of such fraction. Such adjustments will take effect (i) if a record date shall have been fixed for determining the stockholders or security holders, as applicable, of the Company entitled to receive such dividend, distribution or issuance by reclassification, as the case may be, immediately after such record date, (ii) otherwise, immediately after the effective date of such dividend, distribution, subdivision, combination, or issuance by reclassification, as the case may be.

 

(b)                                 Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or a series of related transactions, (A) effects any merger, consolidation or reorganization or other similar transaction or a series of related transactions which results in the voting securities of the Company outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power of the voting securities of or economic interests in the Company or such surviving or acquiring entity outstanding immediately after such merger, consolidation or reorganization, (B) effects any sale, lease, license, assignment, transfer, conveyance, distribution or other disposition of all or substantially all of its assets, (C) effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (except for issuances by reclassification contemplated by Section 11(a)(iv)), or (D) consummates a stock or share purchase agreement or other business combination (including a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) whereby such other Person or “group” acquires more than 50% of the voting power of or economic interests in the then outstanding shares of capital stock of the Company (after giving effect to such transaction), or (ii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person or group of Persons) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property (each transaction or series of transactions referred to in clause (i) or (ii) above, a “Fundamental Transaction”); then, the Company shall ensure that lawful and adequate provision shall be made whereby the Holder shall thereafter continue to have the right to purchase and receive upon the basis and upon the terms and conditions herein specified, and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities or assets as the Holder would have been entitled to receive upon the occurrence of such Fundamental Transaction as if the Holder had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares immediately theretofore issuable upon exercise of this Warrant (the “Underlying Shares”). If the Fundamental Transaction constitutes a Change of Control and such Change of Control occurs on or before December 31, 2016, then the Holder shall also be entitled to surrender this Warrant at any time following the consummation of the Change of Control in exchange for a cash payment equal to the aggregate value of this Warrant (the “Aggregate Value”), where the Aggregate Value is equal to the product obtained by multiplying the output of the Black-Scholes Option Pricing formula set forth in Attachment C hereto times the number of Underlying Shares; provided, however, that if the Aggregate Value exceeds the product obtained by multiplying $0.125 (as adjusted for any stock splits, stock dividends, recapitalizations or the like after the Issuance Date) times the number of Underlying Shares (such product, the “Maximum Payment”), then such cash payment to the Holder shall equal the Maximum Payment.  For purposes of this Section 11(b), a “Change of Control” means any Fundamental Transaction other than (i) with respect to the transactions contemplated by Section 11(b)(i)(C), any reclassification, reorganization, recapitalization or compulsory share exchange in which the holders of the voting securities of the Company outstanding immediately prior thereto continue after such reclassification, reorganization, recapitalization or compulsory share exchange to hold publicly traded securities and 50% or more of the combined voting power of the voting securities of or economic interests in the Company or any surviving or acquiring entity, or (ii) with respect to the transactions contemplated by Section 11(b)(ii), any purchase, tender or exchange offer that is accepted by the holders of less than 50% of the voting power of or economic interests in the then outstanding shares of capital stock of the Company.

 

7

 

Moreover, appropriate provision shall be made with respect to the rights and interests of each Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any such shares of stock, securities or assets thereafter deliverable upon the exercise thereof. The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof the successor corporation resulting from such consolidation or merger, or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume by written instrument, reasonably deemed by the Board of Directors to be satisfactory in form and substance, the obligation to deliver to the Holder, at the last address of such Holder appearing on the books of the Company, such shares of stock, securities or assets, as, in accordance with the foregoing provisions, the Holder may be entitled to purchase upon exercise of this Warrant, and the other obligations under this Warrant. The provisions of this Section 11(b) shall similarly apply to successive Fundamental Transactions.

 

(c)                                  Adjustment Rules.

 

(i)                                     Any adjustments pursuant to this Section 11 shall be made successively whenever any event referred to herein shall occur, except that, notwithstanding any other provision of this Section 11, no adjustment shall be made to the number of Warrant Shares to be delivered to the Holder (or to the Exercise Price) if such adjustment represents less than 1% of the number of Warrant Shares previously required to be so delivered, but any lesser adjustment shall be carried forward and shall be made at the time and together with the next subsequent adjustment which together with any adjustments so carried forward shall amount to 1% or more of the number of Warrant Shares to be so delivered.

 

(ii)                                  No adjustments shall be made pursuant to this Section 11 in respect of the issuance of Warrant Shares upon exercise of the Warrant.

 

(iii)                               If the Company shall take a record of the holders of its shares for any purpose referred to in this Section 11, then (x) such record date shall be deemed to be the date of the issuance, sale, distribution or grant in question and (y) if the Company shall legally abandon such action prior to effecting such action, no adjustment shall be made pursuant to this Section 11 in respect of such action.

 

(iv)                              In computing adjustments under this Section 11, (A) fractional interests in Shares shall be taken into account to the nearest one-thousandth of a Share, and (B) calculations of the Exercise Price shall be carried to the nearest one-thousandth of one cent.

 

(d)                                 Proceedings Prior to Any Action Requiring Adjustment.  Subject to the below proviso, as a condition precedent to the taking of any action which would require an adjustment pursuant to this Section 11, the Company shall take any action which may be necessary, including obtaining regulatory approvals or exemptions, in order that the Company may thereafter validly and legally issue as fully paid and nonassessable all Warrant Shares which the Holder is entitled to receive upon exercise of the Warrant; provided, however, that, notwithstanding the foregoing, effecting the Increased Shares Amendment shall not be a condition precedent to the taking of any action which would require an adjustment pursuant to this Section 11.

 

(e)                                  Notice of Adjustment. Not less than 20 days prior to the record date or effective date, as the case may be, of any action which requires or might require an adjustment or readjustment pursuant to this Section 11, the Company shall give notice to the Holder of such event, describing such event in reasonable detail and specifying the record date or effective date, as the case may be, and, if determinable, the required adjustment and computation thereof. If the required adjustment is not determinable as the time of such notice, the Company shall give notice to the Holder of such adjustment and computation as soon as reasonably practicable after such adjustment becomes determinable. In connection with any such adjustment or readjustment, the Company shall prepare a report setting forth such adjustment or readjustment and showing in reasonable detail the method of calculation thereof and the facts upon which such adjustment or readjustment is based, including a statement of (i) the number of Shares outstanding or deemed to be outstanding, and (ii) the Exercise Price in effect immediately prior to such issue or sale and as adjusted and readjusted (if required by this Section 11) on account thereof. The

 

8

 

Company will forthwith mail a copy of each such report to the Holder and will, upon the written request at any time of the Holder, furnish to such holder a like report setting forth the Exercise Price at the time in effect and showing in reasonable detail how it was calculated. The Company will also keep copies of all such reports at its office and will cause the same to be available for inspection at such office during normal business hours by the Holder.

 

(f)                                   Disputes. Any dispute which arises between the Holder and the Company with respect to the calculation of the adjusted Exercise Price or Warrant Shares issuable upon exercise shall be determined by the independent auditors of the Company in accordance with the terms of this Warrant, and such determination shall be binding upon the Company and the holders of the Warrants and the Warrant Shares if made in good faith and without manifest error. furnish to the Holder the Exercise Price resulting from such adjustment or otherwise in effect and the number of Warrant Shares then available for purchase under this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.

 

12.                               [Intentionally Omitted][Limitation on Exercise]. Notwithstanding anything to the contrary contained herein, the number of Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by the Holder and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act, does not exceed 9.999% of the total number of then issued and outstanding shares of Common Stock (including for such purpose the Warrant Shares issuable upon such exercise). For such purposes, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to such Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and such Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 12 applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 12, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three Business Days confirm orally and in writing to such Holder the number of outstanding shares of Common Stock. This provision shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a transaction contemplated in Section 11 of this Warrant. By written notice to the Company, which will not be effective until the 61st day after such notice is delivered to the Company, the Holder may waive or amend the provisions of this Section 12 to change the beneficial ownership limitation to any other number, and the provisions of this Section 12 and Section 13 shall continue to apply.](2)

 

13.                               Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, for a number of Warrant Shares in excess of that number of Warrant Shares that, upon giving effect to such exercise, would cause (a) the aggregate number of shares of Common Stock beneficially owned by such Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the

 

(2)  This limitation on exercise provision shall be includable only in BVF Partners’ warrant (or in any other Purchaser’s warrant that specifically requests the inclusion of this provision in its warrant to be issued at the Closing).

 

9

 

Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 38.5% of the total number of shares of the Common Stock outstanding following such exercise, or (b) the combined voting power of the securities of the Company beneficially owned by such Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 38.5% of the combined voting power of all of the securities of the Company outstanding following such exercise. For purposes of the foregoing sentence, the number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude shares of Common Stock or other voting securities which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 13. Except as set forth in the preceding sentence, for purposes of this Section 13, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. The provisions of this Section 13 shall be construed, corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein contained.

 

14.                               No Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay the Holder an amount of cash equal to the product of such fraction multiplied by the Fair Market Value of one share of Common Stock on the Date of Exercise.

 

15.                               No Impairment. The Company shall not by any action including, without limitation, amending its Certificate of Incorporation, any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action, as may be necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of the foregoing, the Company shall take all such action as may be necessary or appropriate, including by taking the actions set forth in Section 6.12 of the Purchase Agreement, in order that the Company may, from and after the Authorized Shares Increase Date, validly issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant at the then Exercise Price therefor.

 

16.                               No Rights as a Stockholder; Notice to Holder. Nothing contained in this Warrant shall be construed as conferring upon the Holder the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, or any rights whatsoever as a stockholder of the Company.

 

17.                               Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

 

18.                               Miscellaneous.

 

(a)                                 Notices. Any and all notices or other communications or deliveries hereunder (including any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number pursuant to this Section 18(a) prior to 5:30 p.m. (New York City time) on a Trading Day, (ii) the next Trading Day after the date of

 

10

 

transmission, if such notice or communication is delivered via facsimile at the facsimile number specified pursuant to this Section 18(a) on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by nationally recognized overnight courier service to the street address specified pursuant to this Section 18(a), or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be as follows:

 

(i) if to the Company, to:

 

GTx, Inc.

175 Toyota Plaza

7th Floor

Memphis Tennessee

Attn: Principal Financial Officer or Chief Legal Officer

Facsimile: (901) 844-8075

 

with a copy to (which shall not constitute notice to the Company):

 

Cooley LLP

3175 Hanover Street

Palo Alto, CA 94304

Attn: Chadwick L. Mills

Facsimile: (650) 849-7400

 

(ii) if to the Holder, to the address, facsimile number or street address appearing on the Warrant Register (which shall initially be the facsimile number and street address set forth for the initial Holder in the Purchase Agreement);

 

or to such other address, facsimile number or email address as the Company or the Holder may provide to the other in accordance with this Section 18(a).

 

(b)                                 Assignment. Subject to the restrictions on transfer described herein and in the Purchase Agreement, the rights and obligations of the Company and the Holder shall be binding upon, and inure to the benefit of, the successors, assigns, heirs, administrators and transferees of the parties. Without the prior written consent of the Holder, which may be withheld in the Holder’s sole discretion, this Warrant may not be assigned by the Company except to a successor in the event of a Fundamental Transaction.

 

(c)                                  No Third Party Beneficiaries. Nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.

 

(d)                                 Amendments; Waiver.  Any term of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the Holder.  No waiver of any default with respect to any provision, condition or requirement of this Warrant shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(e)                                  Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles of conflict of laws.

 

(f)                                   Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law in any respect, such provision shall be excluded from this Warrant and the balance of this Warrant shall be construed and interpreted as if such provision were so excluded and shall be enforceable in accordance with its remaining terms.

 

11

 

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

 

12

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

 

	
 
    	
GTx, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
Marc   S. Hanover
    
	
 
    	
Title:
    	
President,   Chief Operating Officer and interim Chief
    
	
 
    	
 
    	
Executive   Officer
    

 

[Signature Page — Warrant]

 

 

ATTACHMENT A

 

EXERCISE NOTICE

 

To GTx, Inc.:

 

The undersigned hereby irrevocably elects to purchase shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), of GTx, Inc., a Delaware corporation, pursuant to Warrant No. CSW2014-[·], originally issued on November [·], 2014 (the “Warrant”). The undersigned elects to utilize the following manner of exercise:

 

Shares:

 

	
 
    	
 
    	
 
    
	
 
    	
     
    	
Full Exercise of Warrant
    
	
 
    	
     
    	
Partial Exercise of Warrant (in the amount of                     Shares)
    
	
 
    
	
 
    	
Exercise   Price:   $                    
    
	
 
    	
 
    
	
 
    	
The   Holder intends that payment of the Exercise Price shall be made as (check   one): *
    
	
 
    
	
 
    	
     
    	
“Net   Exercise” under Section 7(b) of the Warrant
    
	
 
    	
     
    	
Certified   or Official Bank Check
    
	
 
    	
     
    	
Intra-Bank   Account Transfer
    
	
 
    	
     
    	
Wire   Transfer
    

 

[Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of the [undersigned]/[the undersigned’s nominee as is specified below].]

 

	
Date:
    	
 
    	
 
    
	
Full Name of Holder†:
    	
 
    	
 
    
	
Signature of Holder or Authorized Representative:
    	
 
    	
 
    
	
Name and Title of Authorized Representative††:
    	
 
    	
 
    
	
Additional Signature of Holder (if jointly held):
    	
 
    	
 
    
	
Social Security or Tax Identification Number:
    	
 
    	
 
    
	
Address of Holder:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Full Name of Nominee of Holder††:
    	
 
    	
 
    
	
Address of Nominee of Holder††:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    

 

	
*
    	
Payable   unless Mandatory Cash Settlement is required pursuant to Section 6(c) of   the Warrant at the time this Warrant is being exercised.
    
	
 
    	
 
    
	
†
    	
Must   conform in all respects to name of holder as specified on the face of the   Warrant.
    
	
 
    	
 
    
	
††
    	
If   applicable.
    

 

 

ATTACHMENT B

 

FORM OF ASSIGNMENT

 

[To be completed and signed only upon transfer of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto [·] the right represented by the attached Common Stock Warrant to purchase [·] shares of Common Stock of GTx, Inc., a Delaware corporation (the “Company”), to which the Warrant relates and appoints [·] as attorney to transfer said right on the books of the Company with full power of substitution in the premises.

 

	
Date:
    	
 
    	
 
    
	
Full Name of Holder*:
    	
 
    	
 
    
	
Signature of Holder or Authorized Representative:
    	
 
    	
 
    
	
Name and Title of Authorized Representative†:
    	
 
    	
 
    
	
Additional Signature of Holder (if jointly held):
    	
 
    	
 
    
	
Address of Holder:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Full Name of Transferee:
    	
 
    	
 
    
	
Address of Transferee:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
In   the presence of:
    	
 
    	
 
    

 

	
*
    	
Must   conform in all respects to name of holder as specified on the face of the   Warrant.
    
	
 
    	
 
    
	
†
    	
If   applicable.
    

 

 

ATTACHMENT C

 

Black-Scholes Option Pricing formula to be used when calculating the value of each Warrant to purchase one Warrant Share shall be:

 

CCorp = SCorpe-l(TCorp-tCorp)N(d1) — KCorpe-r(TCorp-tCorp)N(d2), where

 

CCorp = value of each Warrant to purchase one Warrant Share

 

SCorp = price of the Common Stock as determined by reference to the average of the closing prices on the Principal Trading Market over the 20-day period ending three Trading Days prior to the closing of the Change of Control described in Section 11(b) if the Common Stock is then traded on an Eligible Market, or the average of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over the 20-day period ending three Trading Days prior to the closing of the Change of Control if the Common Stock is then actively traded in the over-the-counter market, or the then most recently completed financing if the Common Stock is not then traded on an Eligible Market or in the over-the-counter market.

 

TCorp = the Expiration Date

 

tCorp = date of public announcement of the Change of Control

 

TCorp-tCorp = time until the Expiration Date, expressed in years

 

s = volatility = the annualized standard deviation of daily log-returns (using a 262-day annualization factor) of the Company’s stock price on the Principal Trading Market over a 20-day trading period, determined by the Holder, that is within the 100-day trading period ending on the Trading Day immediately after the public announcement of the Change of Control described in Section 11(b) if the Common Stock is then traded on an Eligible Market, or the annualized standard deviation of daily-log returns (using a 262-day annualization factor) of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over a 20-day trading period, determined by the Holder, that is within the 100-day trading period ending on the Trading Day immediately after the public announcement of the Change of Control if the Common Stock is then actively traded in the over-the-counter market, 0.4 (or 40%) if the Common Stock is not then traded on an Eligible Market or in the over-the-counter market; provided, however, that volatility shall not exceed 0.4 (or 40%) regardless of the method of calculation.

 

N = cumulative normal distribution function

 

d1 = (ln(SCorp/KCorp) + (r-l+s2/2)(TCorp-tCorp)) ÷ (sÖ(TCorp-tCorp))

 

ln = natural logarithm

 

l = dividend rate of the Company for the most recent 12-month period at the time of closing of the Fundamental Transaction.

 

KCorp = the Exercise Price as determined pursuant to Section 3

 

r = annual yield, as reported by Bloomberg at time tCorp, of the United States Treasury security measuring the nearest time TCorp

 

d2 = d1- sÖ(TCorp-tCorp)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]